Evaluation of Somatostatin and Dopamine Receptor Subtype 2 Expression in Pancreatic Neuroendocrine Neoplasms

#1581

Introduction: Although somatostatin receptor subtype 2 (SSTR2) and dopamine type 2 receptor (D2R) are reported to be expressed in neuroendocrine neoplasms (NEN), there is a lack of data from studies on a large number of patients with pancreatic NEN.

Aim(s): To evaluate the expression of SSTR2 and D2R in pancreatic NEN.

Materials and methods: A total of 109 pancreatic NEN cases (median age 55 years, 44% male, 73% non-functioning tumors, 74% NET G1) that had undergone curative resection in our hospital were studied. Expression of SSTR2 and D2R was evaluated immunohistochemically using resected specimens. Several clinicopathological factors that affect the expression rate of SSTR2 and D2R were analyzed.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lee L

Authors: Lee L, Ito T, Kawabe K, Otsuka T, Nakamura M,

Keywords: Somatostatin receptor, dopamine receptor, SSTR2, D2R,

To read the full abstract, please log into your ENETS Member account.